Figure 2 shows the dissolution profile obtained with a formulation identical to that of the invention but containing no L-tartaric acid; and

Figure 3 shows the curves of the plasma kinetics of a pharmaceutical form according to the invention containing 10 mg of mizolastine studied in a healthy volunteer after a single oral administration, compared with a standard immediate-release gelatin capsule containing 10 mg of mizolastine.--

IN THE ABSTRACT:

Add the Abstract of the Disclosure appended hereto.

IN THE CLAIMS:

Claim 1, lines 2-3, change "characterized in that it contains" to --comprising--;

line 5, delete "with" and "said".

Claim 2, line 2, change "characterized in that" to --wherein--.

3. (Amended) Sustained-release pharmaceutical formulation according to [either of Claims 1 and 2] Claim 1, wherein [characterized in that] the fatty matrix is selected from the group consisting of [made with] hydrogenated castor oil, a [or with] hydrogenated lecithin, a [lecithin or] long-chain fatty acid and a triglyceride [acids or triglycerides] esterified with one, two or three medium-chain fatty acids.